🔎 Trials Near Me

Utama › Kegagalan Ginjal › Tennessee

Kajian klinikal Kegagalan Ginjal di Tennessee

7 kajian untuk Kegagalan Ginjal sedang mencari peserta di lokasi di Tennessee.

Bandar di Tennessee

Teks kajian rasmi (Bahasa Inggeris)

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  • Southeast Renal Research Institute, Chattanooga
  • Dialysis Clinic Inc - University Nephology, Knoxville
  • Knoxville Kidney Center PLLC, Knoxville
  • dan 2 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05485961

Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)

  • Memphis VA Medical Center, Memphis, TN, Memphis
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT05465044

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

  • Vascular Institute of Chattanooga, Chattanooga
  • Bluff City Vascular, Memphis
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT04634916

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

  • Nephrology Associates of Knoxville, Knoxville
Mengambil peserta
Umur 18 hingga 80 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06613568

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

  • Galen Medical Group, Chattanooga
Mengambil peserta
Umur 18 hingga 84 · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06190717

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

  • James Eric Gardner, MD, PC, Memphis
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Feb 2026 · NCT06001827

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

  • Vanderbilt University Medical Center-GCRC, Nashville
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Jan 2026 · NCT05422534

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.